Preparation and properties of sterically stabilized hexadecylphosphocholine (miltefosine)-liposomes and influence of this modification on macrophage activation

Biochimica et Biophysica Acta - Biomembranes

Volumn 1283, Issue 2, 1996, Pages 177-184

  Zeisig, Reiner ^a   Eue, Ines ^a   Kosch, Markus ^b   Fichtner, Iduna ^a   Arndt, Dieter ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Hexadecylphosphocholine; Liposome; LUVET; Macrophage; Mononuclear phagocytic system; Poly(ethylene glycol); Stabilty

Indexed keywords

LIPOSOME; MACROGOL; MILTEFOSINE; NITRIC OXIDE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; MACROPHAGE ACTIVATION; MEASUREMENT; MOLECULAR STABILITY; MOUSE; NONHUMAN; PARTICLE SIZE; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; SURFACE PROPERTY;

ANIMALIA;

EID: 0030568866     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/0005-2736(96)00090-9     Document Type: Article

References (44)

1. [1] Eibl, H., Hilgard, P. and Unger, C., (eds.) (1992) Alkylphosphocholines: New drugs in cancer therapy, S. Karger, Basel.
2. [2] Eibl, H. and Unger, C. (1990) Cancer Treat. Rep. 17, 233-242.
3. [3] Zeisig, R., Fichtner, I., Arndt, D. and Jungmann, S. (1991) Anti-Cancer Drugs 2, 411-417.
4. [4] Fichtner, I., Zeisig, R., Naundorf. H., Jungmann, S., Arndt, D., Asongwe, G., Double, J.A. and Bibby, M.C. (1994) Breast Cancer Res. Treat. 32, 269-279.
5. [5] Unger, C., Sindermann, H., Peukert, M., Hilgard, P., Engel, J. and Eibl, H. (1992) Prog. Exp. Tumor Res. 34, 153-159.
6. [6] Planting, A.S.T., Stoter, G. and Verweij, J. (1993) Eur. J. Cancer 29A, 518-519.
7. [7] Verweij, J., Gandia, D., Planting, A.S.T., Stoter, G. and Armand, J.P. (1993) Eur. J. Cancer 29, 778-779.
8. [8] Woodle, M.C. and Lasic, D. (1992) Biochim. Biophys. Acta 1113, 171-199.
9. [9] Senior, J., Crawley, J.C. and Gregoriadis, G. (1985) Biochim. Biophys. Acta 839, 1-8.
10. [10] Allen, T.M., Austin, G.A., Chonn, A., Lin, L. and Lee, K.C. (1991) Biochim. Biophys. Acta 1061, 56-64.
11. [11] Schroit, I.J. and Fidler, I.J. (1982) Cancer Res. 42. 161-167.
12. [12] Roerdink, F.H., Regts, J., Handel, T., Sullivan, S.M., Baldeschwieler, J.D. and Scherphof, G.L. (1989) Biochim. Biophys. Acta 980, 234-240.
13. [13] Kirby, C., Clarke. J. and Gregoriadis, G. (1980) Biochem. J. 186. 591-598.
14. [14] Lee, K.-D., Hong, K. and Paphadjopoulos, D. (1992) Biochim. Biophys. Acta 1103, 185-197.
15. [15] Allen, T.M. and Hansen. C. (1991) Biochim. Biophys. Acta 1068, 133-141.
16. [16] Allen, T.M., Hansen, C., Martin, F., Redemann, C. and Yau-Young, A. (1991) Biochim. Biophys. Acta 1066, 29-36.
17. [17] Papahadjopoulos, D., Allen, T.M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S.K., Lee, K.D., Woodle, M.C., Lasic, D.D., Redemann, C. and Martin, F.J. (1991) Proc. Natl. Acad. Sci. USA 88, 11460-11464.
18. [18] Blume. G., Cevc, G.. Crommelin, M.D.J.A., Bakker-Woudenberg, I.A.J.M., Kluft, C. and Storm, G. (1993) Biochim. Biophys. Acta 1149, 180-184.
19. [19] Yuan, F., Leunig, M., Huang, S.K., Berk, D.A., Papahadjopoulos, D. and Jain, R.K. (1994) Cancer Res. 54, 3352-3356.
20. [20] Wu, N., Da, D., Rudoll, T., Needham, D., Whorton, R. and Dewhurst, M. (1993) Cancer Res. 53, 3765-3770.
21. [21] Zeisig, R., Jungmann, S., Arndt, D., Schütt, A. and Nissen, E. (1993) Anti-Cancer Drugs 4, 57-64.
22. [22] Zeisig, R., Rudolf, M., Eue, I. and Arndt, D. (1995) J. Cancer Res. Clin. Oncol. 121. 69-75.
23. [23] Eue, I., Zeisig, R. and Arndt, D. (1995) J. Cancer Res. Clin. Oncol. 121, 350-356.
24. [24] Zeisig, R., Arndt, D., Jungmann, S. and Daemen, T. (1994) Anti-cancer Res. 14, 1785-1790.
25. [25] Weinstein, J.N., Ralston, E., Lesermann L.D., Klausner, R.D., Dragsten. P., Henkart, P. and Blumenthal, R. (1983) in Liposome Technology (Gregoriadis, G., ed.). Vol. 3, pp. 183-204, CRC Press, Boca Raton.
26. [26] MacDonald, R.C., MacDonald, R.I., Menco, B.P.M., Takeshita, K., Subbarao, N.K. and Hu. L. (1991) Biochim. Biophys. Acta 1061, 297-303.
27. [27] Allen, T.M. and Cleland, L.G. (1980) Biochim. Biophys. Acta 597, 418-426.
28. [28] Hilgard, P., Stekar, J., Voegeli, R., Engel, J., Schumacher, W., Eibl, H., Unger, C. and Berger, M.R. (1988) Eur. J. Cancer Clin. Oncol. 24, 1457-1461.
29. [29] Espevik, T. and Nissen-Meyer. J. (1986) J. lmmunol. Methods 95, 99-105.
30. [30] Ding. A.H., Nathan, C.F. and Stuehr, D.J. (1988) J. Immunol. 141, 2407-2412.
31. [31] Fichtner, I., Kniest, A. and Arndt, D. (1992) In Vivo 6, 113-117.
32. [32] Huang, S.K., Mayhew, E., Gilani, S., Lasic, D.D., Martin, F.J. and Papahadjopoulos, D. (1992) Cancer Res. 52, 6774-6781.
33. [33] Jousma, H., Talsma, H., Spies, F., Joosten, J.G.H., Junginger, H.E. and Crommelin, D.J.A. (1987) J. Pharm. 35, 263-274.
34. [34] Hope, M.J., Bally, M.B., Webb, G. and Cullies, P.R. (1985) Biochim. Biophys. Acta 812. 55-65.
35. [35] Kaufmann-Kolle, P., Unger, C. and Eibl, H. (1992) in Progress in experimental tumor research (Eibl, H., Hilgard, P. and Unger, C., eds. ), Vol. 34, New drugs in cancer therapy, pp. 12-24, S. Karger, Basel.
36. [36] Unger, C., Fleer, E., Damenz, W., Hilgard, P., Nagel, G. and Eibl, H. (1991) J. Lipid Mediat. 3, 71-78.
37. [37] Firegold, L. and Singer, M.A. (1991) Chem. Phys. Lipids 58, 169-173.
38. [38] Kirby, C., Clarke, J. and Gregoriadis, G. (1980) Biochem. J. 186, 591-598.
39. [39] Mercadal, M., Domingo, J.C., Bermudez, M., Mora, M. and Madariaga, M.A. (1995) Biochim. Biophys. Acta 1235, 281-288.
40. [40] Kronberg, B., Dahlman, A., Carlfors, J., Karlsson, J. and Artursson, P. (1990) J. Pharm. Sci. 79, 667-671.
41. [41] Blume, G. and Cevc, G. (1993) Biochim. Biophys. Acta 1146, 157-168.
42. [42] Liu, D., Zhou, F. and Huang, L. (1989) Biochem. Biophys. Res. Commun. 162, 326-333.
43. [43] Cunha, F.Q., Assreuy, J., Moncada, S. and Liew, F.Y. (1993) Immunology 79, 408-411.
44. [44] Higuchi, M., Higashi, N., Taki, H. and Osawa. T. (1990) J. Immunol. 144, 1425-1431.